Virtual Library

Start Your Search

Niloufar Mobashery



Author of

  • +

    P2.01 - Advanced NSCLC (ID 159)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Advanced NSCLC
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.01-26 - EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC (ID 2173)

      10:15 - 18:15  |  Author(s): Niloufar Mobashery

      • Abstract
      • Slides

      Background

      Most patients (pts) with non-small cell lung cancer (NSCLC) present with advanced disease at the time of diagnosis. Until recently, platinum-based doublet chemotherapy regimens were the standard of care first-line treatment for pts with advanced NSCLC whose tumors lack an EGFR, ALK, or ROS1 mutation. Despite chemotherapy, patients with metastatic NSCLC had a median overall survival (OS) of 8 to 12 months and a 5-year survival rate of approximately 18%. With the introduction of programmed cell death-1 (PD-1) inhibitors to NSCLC, this prognosis has improved. Cemiplimab, a human PD-1 monoclonal antibody, has exhibited antitumor activity and safety in a Phase 1 trial of advanced malignancies including NSCLC and was approved recently in the US as cemiplimab-rwlc for advanced cutaneous squamous cell carcinoma (CSCC). Based on their unique modes of action, combining cemiplimab with platinum‑based chemotherapy has the potential for a synergistic effect in pts with advanced NSCLC of both histologies and irrespective of PD-L1 expression.

      Method

      EMPOWER-lung 3 is a randomised, global, two-part, Phase 3 study of first-line treatment of pts with advanced squamous or non-squamous NSCLC (NCT03409614). Part 1, as previously described (IASLC 19th WCLC; Abstract 13347), is open-label and aims to describe the efficacy and safety of combinations of cemiplimab, ipilimumab, and platinum-based doublet chemotherapy in pts whose tumors express PD-L1 in <50% of the tumor cells. The updated primary endpoint of Part 1 is objective response rate.

      Here we introduce the recently added Part 2. This part is double-blinded and will compare the efficacy and safety of cemiplimab versus placebo, both in combination with investigator’s choice of standard chemotherapy, in all pts irrespective of PD-L1 expression status. Chemotherapy options include: paclitaxel + carboplatin or cisplatin for squamous cell NSCLC and pemetrexed + carboplatin or cisplatin for non-squamous NSCLC. The investigator may choose from one of these regimens provided that it is consistent with the local standard-of-care. Pts will be randomized (2:1) to cemiplimab 350 mg Q3W plus up to four cycles of chemotherapy or placebo Q3W plus up to four cycles of chemotherapy. Pts will be stratified by histology and PD-L1 expression levels. The co-primary endpoints for Part 2 are OS and progression-free survival (PFS).

      Result

      Section not applicable

      Conclusion

      Section not applicable

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.